Dyadic International Inc
NASDAQ:DYAI
Intrinsic Value
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. [ Read More ]
The intrinsic value of one DYAI stock under the Base Case scenario is 2.25 USD. Compared to the current market price of 1.67 USD, Dyadic International Inc is Undervalued by 26%.
Valuation Backtest
Dyadic International Inc
Run backtest to discover the historical profit from buying and selling DYAI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Dyadic's Productivity Surge and Revenue Prospects
2023-Q3 Earnings Call
Dyadic accelerated momentum in 2023 with its innovative C1 technology and Dapibus platform, making strides in protein and enzyme production for pharmaceutical and non-pharmaceutical markets. They reported advancements such as animal-free recombinant serum albumin close to commercialization and productivity unmatched by traditional platforms - C1 is up to 300x more productive than some methods. Despite global economic headwinds affecting R&D funding, Dyadic secured new partnerships, upfront payments, and fully funded projects, with prospects of near-term revenue from high-value products that bypass lengthy trials. The potential for consistent revenue comes from an internal product pipeline and external collaborations expected to mature in the coming year.
Balance Sheet Decomposition
Dyadic International Inc
Current Assets | 9.1m |
Cash & Short-Term Investments | 8.2m |
Receivables | 430k |
Other Current Assets | 490k |
Non-Current Assets | 170k |
PP&E | 150k |
Other Non-Current Assets | 20k |
Current Liabilities | 1.5m |
Accrued Liabilities | 670k |
Other Current Liabilities | 790k |
Non-Current Liabilities | 140k |
Other Non-Current Liabilities | 140k |
Earnings Waterfall
Dyadic International Inc
Revenue
|
3m
USD
|
Cost of Revenue
|
-2.3m
USD
|
Gross Profit
|
620k
USD
|
Operating Expenses
|
-8.9m
USD
|
Operating Income
|
-8.2m
USD
|
Other Expenses
|
1.4m
USD
|
Net Income
|
-6.9m
USD
|
Free Cash Flow Analysis
Dyadic International Inc
What is Free Cash Flow?
DYAI Profitability Score
Profitability Due Diligence
Dyadic International Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Dyadic International Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
DYAI Solvency Score
Solvency Due Diligence
Dyadic International Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Dyadic International Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DYAI Price Targets Summary
Dyadic International Inc
According to Wall Street analysts, the average 1-year price target for DYAI is 7.65 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.
Ownership
DYAI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DYAI Price
Dyadic International Inc
Average Annual Return | -4.51% |
Standard Deviation of Annual Returns | 54.52% |
Max Drawdown | -88% |
Market Capitalization | 48.1m USD |
Shares Outstanding | 28 811 100 |
Percentage of Shares Shorted | 0.85% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida and currently employs 7 full-time employees. The company went IPO on 2004-11-05. The firm is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The firm is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.
Contact
IPO
Employees
Officers
The intrinsic value of one DYAI stock under the Base Case scenario is 2.25 USD.
Compared to the current market price of 1.67 USD, Dyadic International Inc is Undervalued by 26%.